Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 17/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9337016 | 1.00 | MME (0.52) | MMECA1CA2ALDH1A1 | |
| SCHEMBL6429465 | 0.90 | MME (0.50) | MMECA1CA2ALDH1A1 | |
| SCHEMBL9753583 | 0.89 | MME (0.44) | MMEALDH1A1 | |
| SCHEMBL5924842 | 0.89 | MME (0.44) | MMEALDH1A1 | |
| SCHEMBL9753833 | 0.88 | MME (0.49) | MMEALDH1A1 | |
| SCHEMBL5925056 | 0.88 | MME (0.49) | MMEALDH1A1 | |
| SCHEMBL5796118 | 0.87 | MME (0.48) | MMEALDH1A1 | |
| SCHEMBL7451242 | 0.84 | MME (0.59) | MME | |
| SCHEMBL8894558 | 0.82 | MME (0.48) | MMEALDH1A1 | |
| SCHEMBL8733280 | 0.82 | MME (0.48) | MMEALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050070499-A1 | Compounds for the treatment of female sexual dysfunction | PFIZER INC. | 2005-03-31 | — | — | US | disclosed |
| US-20050020547-A1 | Compounds for the treatment of female sexual dysfunction | PFIZER INC. | 2005-01-27 | — | — | US | disclosed |
| EP-1097719-B1 | NEP inhibitors for the treatment of female sexual dysfunction | PFIZER LTD (GB) | 2004-12-22 | — | — | EP | disclosed |
| US-20040254153-A1 | Compounds for the treatment of female sexual dysfunction | PFIZER INC | 2004-12-16 | — | — | US | disclosed |
| EP-1481667-A1 | NEP inhibitors for the treatment of female sexual dysfunction | Pfizer Limited (GB) | 2004-12-01 | — | — | EP | disclosed |
| US-6734186-B1 | PHOSPHODIESTERASE 2 INHIBITOR | PFIZER INC. | 2004-05-11 | — | — | US | disclosed |
| EP-1296938-A1 | CYCLOPENTYL-SUBSTITUTED GLUTARAMIDE DERIVATIVES AS INHIBITORS OF NEUTRAL ENDOPEPTIDASE | Pfizer Limited (GB) | 2003-04-02 | — | — | EP | disclosed |
| US-20020052370-A1 | Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase | PFIZER, INC. | 2002-05-02 | — | — | US | disclosed |
| WO-2002002513-A1 | CYCLOPENTYL-SUBSTITUTED GLUTARAMIDE DERIVATIVES AS INHIBITORS OF NEUTRAL ENDOPEPTIDASE | PFIZER LIMITED (GB) | 2002-01-10 | — | — | WO | disclosed |
| EP-1097707-A1 | Treatment of female sexual dysfunction | Pfizer Limited (GB) | 2001-05-09 | — | — | EP | disclosed |
| EP-1097706-A1 | Phosphodiesterase inhibitors for the treatment of female sexual dysfunction | Pfizer Limited (GB) | 2001-05-09 | — | — | EP | disclosed |
| EP-1097719-A1 | NEP inhibitors for the treatment of female sexual dysfunction | Pfizer Limited (GB) | 2001-05-09 | — | — | EP | disclosed |
| EP-1097718-A1 | NPY antagonists for the treatment of female sexual dysfunction | Pfizer Limited (GB) | 2001-05-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254153-A1 | Compounds for the treatment of female sexual dysfunction | FSHR, SHBG, PDE3A | MME 2886/4885CA1 2795/4885CA2 2675/4885 |
| US-20020052370-A1 | Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase | ENGASE, ENPEP, CPN1 | MME 7/4885CA1 454/4885CA2 709/4885 |
| US-20050020547-A1 | Compounds for the treatment of female sexual dysfunction | FSHR, SHBG, PDE3A | MME 2886/4885CA1 2795/4885CA2 2675/4885 |
| US-20050070499-A1 | Compounds for the treatment of female sexual dysfunction | FSHR, SHBG, PDE3A | MME 2886/4885CA1 2795/4885CA2 2675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.